LIVIVO - Search results -

Search results

Result 1 - 10 of total 18

Search options

Article: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial.

Tan, Amabel Cl / Goubier, Anne / Kohrt, Holbrook E

2015 Volume 3, Page(s) 48

Abstract: Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a ... ...

Abstract	Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight shifts in trends for the vaccine platforms examined, common adjuvant use, target indications, antibody or treatment combinations between past and recent trials as well as discuss the relationship between these trends and ratio between the number of phase 3: phase 2 for different vaccine platforms. Despite the poor success rate in vaccine approvals, registration of phase 3 trials between 2010 and 2014 were stable indicating continued investment and efforts towards development of immunotherapeutic vaccines.
Language	English
Publishing date	2015
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2719863-7
ISSN	2051-1426
ISSN	2051-1426
DOI	10.1186/s40425-015-0093-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8

Xiang, Sue D / Wilson, Kirsty L / Goubier, Anne / Heyerick, Arne / Plebanski, Magdalena

Frontiers in immunology

2018 Volume 9, Page(s) 2968

Abstract: Gynecological cancers are a leading cause of mortality in women. ... ...

Abstract	Gynecological cancers are a leading cause of mortality in women. CD8
MeSH term(s)	Adjuvants, Immunologic/administration & dosage ; Animals ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Epitopes, T-Lymphocyte/immunology ; Female ; Genital Neoplasms, Female/immunology ; Genital Neoplasms, Female/therapy ; HLA-A2 Antigen/immunology ; HLA-A2 Antigen/metabolism ; Humans ; Immunogenicity, Vaccine ; Mice ; Mice, Transgenic ; Nanoparticles/administration & dosage ; Papillomavirus E7 Proteins/immunology ; Peptides/immunology ; Polystyrenes/administration & dosage ; Survivin/immunology ; Vaccines, Conjugate/administration & dosage ; Vaccines, Conjugate/immunology ; Vaccines, Subunit/administration & dosage ; Vaccines, Subunit/immunology ; WT1 Proteins/immunology
Chemical Substances	Adjuvants, Immunologic ; BIRC5 protein, human ; Cancer Vaccines ; Epitopes, T-Lymphocyte ; HLA-A2 Antigen ; Papillomavirus E7 Proteins ; Peptides ; Polystyrenes ; Survivin ; Vaccines, Conjugate ; Vaccines, Subunit ; WT1 Proteins ; WT1 protein, human ; oncogene protein E7, Human papillomavirus type 16
Keywords	covid19
Language	English
Publishing date	2018-12-21
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2018.02968
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.

Bianchi, Matteo / Reichen, Christian / Croset, Amelie / Fischer, Stefanie / Eggenschwiler, Aline / Grübler, Yvonne / Marpakwar, Rajlakshmi / Looser, Thamar / Spitzli, Patricia / Herzog, Christel / Villemagne, Denis / Schiegg, Dieter / Abduli, Liridon / Iss, Chloé / Neculcea, Alexandra / Franchini, Marco / Lekishvili, Tamara / Ragusa, Simone / Zitt, Christof /

Kaufmann, Yvonne / Auge, Alienor / Hänggi, Martin / Ali, Waleed / Frasconi, Teresa M / Wullschleger, Stephan / Schlegel, Iris / Matzner, Mirela / Lüthi, Ursina / Schlereth, Bernd / Dawson, Keith M / Kirkin, Vladimir / Ochsenbein, Adrian F / Grimm, Sebastian / Reschke, Nina / Riether, Carsten / Steiner, Daniel / Leupin, Nicolas / Goubier, Anne

Cancer immunology research

2024

Abstract: The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit patients not eligible for hematopoietic stem cell (HSC) transplantation. The disease is driven by leukemic stem cells (LSCs), which are characterized ... ...

Abstract	The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit patients not eligible for hematopoietic stem cell (HSC) transplantation. The disease is driven by leukemic stem cells (LSCs), which are characterized by clonal heterogeneity and resistance to conventional therapy. These cells are therefore believed to be a major cause of progression and relapse. We designed MP0533, a multispecific CD3-engaging DARPin (designed ankyrin repeat protein) that can simultaneously bind to three antigens on AML cells (CD33, CD123, and CD70), aiming to enable avidity-driven T cell-mediated killing of AML cells co-expressing at least two of the antigens. In vitro, MP0533 induced selective T cell-mediated killing of AML cell lines, as well as patient-derived AML blasts and LSCs, expressing two or more target antigens, while sparing healthy HSCs, blood, and endothelial cells. The higher selectivity also resulted in markedly lower levels of cytokine release in normal human blood compared to single antigen-targeting T-cell engagers. In xenograft AML mouse models, MP0533 induced tumor-localized T-cell activation and cytokine release, leading to complete eradication of the tumors while having no systemic adverse effects. These studies show that the multispecific-targeting strategy used with MP0533 holds promise for improved selectivity towards LSCs and efficacy against clonal heterogeneity, potentially bringing a new therapeutic option to this group of patients with high unmet need. MP0533 is currently being evaluated in a dose-escalation phase 1 study in patients with relapsed or refractory AML (NCT05673057).
Language	English
Publishing date	2024-04-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	2732489-8
ISSN	2326-6074 ; 2326-6066
ISSN (online)	2326-6074
ISSN	2326-6066
DOI	10.1158/2326-6066.CIR-23-0692
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7022: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.

Esquerré, Michaël / Bouillette-Marussig, Myriam / Goubier, Anne / Momot, Marie / Gonindard, Christophe / Keller, Hélène / Navarro, Astrid / Bissery, Marie-Christine

PloS one

2017 Volume 12, Issue 3, Page(s) e0174038

Abstract: Background: Prophylactic vaccines are available for women and girls not yet infected with HPV, but women already infected with HPV need a treatment to prevent progression to high-grade cervical lesions and cancer. GTL001 is a bivalent therapeutic ... ...

Abstract	Background: Prophylactic vaccines are available for women and girls not yet infected with HPV, but women already infected with HPV need a treatment to prevent progression to high-grade cervical lesions and cancer. GTL001 is a bivalent therapeutic vaccine for eradicating HPV-infected cells that contains HPV16 E7 and HPV18 E7 both fused to detoxified adenylate cyclase from Bordetella pertussis, which binds specifically to CD11b+ antigen-presenting cells. This study examined the ability of therapeutic vaccination with GTL001 adjuvanted with topical imiquimod cream to induce functional HPV16 E7- and HPV18 E7-specific CD8+ T cell responses. Methods: Binding of GTL001 to human CD11b was assessed by a cell-based competition binding assay. Cellular immunogenicity of intradermal vaccination with GTL001 was assessed in C57BL/6 mice by enzyme-linked immunospot assay and in vivo killing assays. In vivo efficacy of GTL001 vaccination was investigated in the TC-1 murine HPV16 E7-expressing tumor model. Results: GTL001 bound specifically to the human CD11b/CD18 receptor. GTL001 adjuvanted with topical 5% imiquimod cream induced HPV16 E7 and HPV18 E7-specific CD8+ T cell responses. This CD8+ T-cell response mediated in vivo killing of HPV E7-expressing cells. In the HPV16 E7-expressing tumor model, GTL001 adjuvanted with imiquimod but not imiquimod alone or a combination of unconjugated HPV16 E7 and HPV18 E7 caused complete tumor regression. Conclusions: GTL001 adjuvanted with topical 5% imiquimod is immunogenic and induces HPV16 E7 and HPV18 E7-specific CD8+ T cell responses that can kill HPV E7-expressing cells and eliminate HPV E7-expressing tumors.
MeSH term(s)	Adjuvants, Immunologic/administration & dosage ; Aminoquinolines/administration & dosage ; Animals ; Antigens, Viral/immunology ; CD11b Antigen/immunology ; CD8-Positive T-Lymphocytes/immunology ; CHO Cells ; Cricetulus ; Female ; Imiquimod ; Mice ; Mice, Inbred C57BL ; Papillomavirus Vaccines/immunology
Chemical Substances	Adjuvants, Immunologic ; Aminoquinolines ; Antigens, Viral ; CD11b Antigen ; ITGAM protein, human ; Papillomavirus Vaccines ; Imiquimod (P1QW714R7M)
Language	English
Publishing date	2017-03-16
Publishing country	United States
Document type	Journal Article
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0174038
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.

Esquerré, Michaël / Momot, Marie / Goubier, Anne / Gonindard, Christophe / Leung-Theung-Long, Stéphane / Misseri, Yolande / Bissery, Marie-Christine

Vaccine

2017 Volume 35, Issue 11, Page(s) 1509–1516

Abstract: GTL001 is a bivalent therapeutic vaccine containing human papillomavirus (HPV) 16 and HPV18 E7 proteins inserted in the Bordetella pertussis adenylate cyclase (CyaA) vector intended to prevent cervical cancer in HPV-infected women with normal cervical ... ...

Abstract	GTL001 is a bivalent therapeutic vaccine containing human papillomavirus (HPV) 16 and HPV18 E7 proteins inserted in the Bordetella pertussis adenylate cyclase (CyaA) vector intended to prevent cervical cancer in HPV-infected women with normal cervical cytology or mild abnormalities. To be effective, therapeutic cervical cancer vaccines should induce both a T cell-mediated effector response against HPV-infected cells and a robust CD8
Language	English
Publishing date	2017-03-13
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2017.01.074
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Understanding CD8

Nguyen, Thi Ho / Tan, Amabel Cl / Xiang, Sue D / Goubier, Anne / Harland, Kim L / Clemens, E Bridie / Plebanski, Magdalena / Kedzierska, Katherine

Clinical & translational immunology

2017 Volume 6, Issue 3, Page(s) e134

Abstract: The Wilms' tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/ ... ...

Abstract	The Wilms' tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/WT1
Language	English
Publishing date	2017-03-17
Publishing country	Australia
Document type	Journal Article
ZDB-ID	2694482-0
ISSN	2050-0068
ISSN	2050-0068
DOI	10.1038/cti.2017.4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Interleukin-4, interleukin-5, and interleukin-13 gene expression in cultured mononuclear cells from porcine circovirus type 2-vaccinated pigs after cells were challenged with porcine circovirus type 2 open reading frame 2 antigen.

Quereda, Juan J / Ramis, Guillermo / Pallarés, Francisco J / Chapat, Ludivine / Goubier, Anne / Joisel, François / Charreyre, Catherine / Villar, David / Muõoz, Antonio

American journal of veterinary research

2013 Volume 74, Issue 1, Page(s) 110–114

Abstract: Objective: To characterize the kinetics of interleukin (IL)-4, IL-5, and IL-13 secretion in peripheral blood and lymph node mononuclear cells isolated from porcine circovirus type 2 (PCV2)-vaccinated pigs after cells were challenged with PCV2 open ... ...

Abstract	Objective: To characterize the kinetics of interleukin (IL)-4, IL-5, and IL-13 secretion in peripheral blood and lymph node mononuclear cells isolated from porcine circovirus type 2 (PCV2)-vaccinated pigs after cells were challenged with PCV2 open reading frame 2 antigen. Animals: 10 pigs. Procedures: 5 pigs were vaccinated with a PCV2 vaccine and received a booster dose 3 weeks later. They were kept together with a similar group of 5 nonvaccinated pigs that served as controls. One week after the second vaccination, peripheral blood mononuclear cells (PBMCs) and excised retropharyngeal lymph node mononuclear cells (LNMCs) were isolated and cultured. Cells were then challenged by exposure to PCV2 open reading frame 2 and evaluated at 2, 12, 24, and 48 hours to determine the expression of IL-4, IL-5, and IL-13 via quantitative PCR assay. Changes in gene expression were analyzed relative to the results from analysis of the sample at 0 hours (calibrator). Results: All ILs were upregulated differently in LNMCs and PBMCs from vaccinated pigs. Lymph node mononuclear cells from vaccinated animals produced significantly more IL-4 mRNA than did PBMCs at 2, 12, and 48 hours (relative change: 2.8 vs -3.6, 13.0 vs 3.6, and 9.8 vs 1.8, respectively) and more IL-5 mRNA at 2, 12, 24, and 48 hours (relative change: 1. 2 vs -4.8, 2.2 vs 0.2, 3.2 vs -1.9, and 4.0 vs -3.6, respectively). Interleukin-13 mRNA reached its highest concentration at 24 hours but was 11.9-fold higher in PBMCs than in LNMCs. Conclusions and clinical relevance: Results supported the importance of IL-4, IL-5, and IL-13 in pigs, suggesting that PBMCs and LNMCs express cytokines in a tissue-specific manner.
MeSH term(s)	Animals ; Antigens, Viral/immunology ; Cells, Cultured ; Circovirus/immunology ; DNA, Complementary/metabolism ; Gene Expression Regulation ; Interleukin-13/genetics ; Interleukin-13/metabolism ; Interleukin-4/genetics ; Interleukin-4/metabolism ; Interleukin-5/genetics ; Interleukin-5/metabolism ; Leukocytes, Mononuclear/metabolism ; Lymphocytes/metabolism ; Open Reading Frames/immunology ; Porcine Postweaning Multisystemic Wasting Syndrome/immunology ; Porcine Postweaning Multisystemic Wasting Syndrome/virology ; RNA/metabolism ; Real-Time Polymerase Chain Reaction/veterinary ; Swine ; Swine Diseases/immunology ; Swine Diseases/virology
Chemical Substances	Antigens, Viral ; DNA, Complementary ; Interleukin-13 ; Interleukin-5 ; Interleukin-4 (207137-56-2) ; RNA (63231-63-0)
Language	English
Publishing date	2013-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	390796-x
ISSN	1943-5681 ; 0002-9645
ISSN (online)	1943-5681
ISSN	0002-9645
DOI	10.2460/ajvr.74.1.110
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 422: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Invariant NKT cells suppress CD8(+) T-cell-mediated allergic contact dermatitis independently of regulatory CD4(+) T cells.

Goubier, Anne / Vocanson, Marc / Macari, Claire / Poyet, Gaelle / Herbelin, André / Nicolas, Jean-François / Dubois, Bertrand / Kaiserlian, Dominique

The Journal of investigative dermatology

2013 Volume 133, Issue 4, Page(s) 980–987

Abstract: Invariant natural killer T (iNKT) cells expressing a CD1d-restricted invariant αβTCR have key regulatory roles in autoimmunity, pathogen immunity, and tumor surveillance, but their function in the control of allergic skin diseases remains poorly ... ...

Abstract	Invariant natural killer T (iNKT) cells expressing a CD1d-restricted invariant αβTCR have key regulatory roles in autoimmunity, pathogen immunity, and tumor surveillance, but their function in the control of allergic skin diseases remains poorly documented. Using a model of contact hypersensitivity (CHS) to the hapten DNFB, we show here that iNKT cell deficiency results in enhanced skin inflammation due to augmented hapten-specific IFN-γ-producing CD8(+) effectors in skin draining lymph nodes (dLNs) and their massive recruitment into the allergen-exposed skin. Adoptive transfer and antibody depletion experiments as well as in vitro studies revealed that iNKT cells (1) reduce the severity of CHS, even in presensitized mice, (2) require hapten presentation by CD1d(+) dendritic cells (DCs) to dampen skin inflammation, and (3) produce IL-4 and IL-13 after CD1d-dependent in vitro stimulation by hapten-loaded DCs only in the presence of IFN-γ released from activated CD8(+) effector T cells. In corollary, mice double deficient in IL-4 and IL-13 exhibit an exacerbated CHS. Finally, iNKT-suppressive function is independent of Foxp3(+) regulatory T cells (Tregs). These data highlight that, besides Foxp3(+) Tregs, iNKT cells are potent downregulators of CD8(+) T cell-mediated CHS, and underscore that both cell types are important for the regulation of allergic skin inflammation.
MeSH term(s)	Animals ; Antigens, CD1d/metabolism ; CD4 Antigens/metabolism ; CD8-Positive T-Lymphocytes/cytology ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Cell Communication/immunology ; Cells, Cultured ; Coculture Techniques ; Dermatitis, Allergic Contact/immunology ; Dermatitis, Allergic Contact/metabolism ; Dermatitis, Allergic Contact/pathology ; Down-Regulation/immunology ; Female ; Flow Cytometry ; Forkhead Transcription Factors/metabolism ; Interferon-gamma/metabolism ; Interleukin-13/genetics ; Interleukin-13/metabolism ; Interleukin-4/genetics ; Interleukin-4/metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Natural Killer T-Cells/cytology ; Natural Killer T-Cells/immunology ; Natural Killer T-Cells/metabolism ; T-Lymphocytes, Regulatory/cytology ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism
Chemical Substances	Antigens, CD1d ; CD4 Antigens ; Cd1d1 protein, mouse ; Forkhead Transcription Factors ; Foxp3 protein, mouse ; Interleukin-13 ; Interleukin-4 (207137-56-2) ; Interferon-gamma (82115-62-6)
Language	English
Publishing date	2013-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80136-7
ISSN	1523-1747 ; 0022-202X
ISSN (online)	1523-1747
ISSN	0022-202X
DOI	10.1038/jid.2012.404
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.124: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Effect of sow vaccination against porcine circovirus type 2 (PCV2) on virological profiles in herds with or without PCV2 systemic disease.

Lopez-Rodriguez, Alfonso / Dewulf, Jeroen / Meyns, Tom / Del-Pozo-Sacristán, Rubén / Andreoni, Christine / Goubier, Anne / Chapat, Ludivine / Charreyre, Catherine / Joisel, François / Maes, Dominiek

The Canadian veterinary journal = La revue veterinaire canadienne

2016 Volume 57, Issue 6, Page(s) 619–628

Abstract: We investigated porcine circovirus type 2 (PCV2) virological profiles in herds affected (PCVAD-AH, n = 5) or non-affected (PCVAD-NAH, n = 4) by PCV2-associated diseases (PCVAD), before and after 1 y of PCV2 gilt and sow vaccination. Fresh feces from the ... ...

Abstract	We investigated porcine circovirus type 2 (PCV2) virological profiles in herds affected (PCVAD-AH, n = 5) or non-affected (PCVAD-NAH, n = 4) by PCV2-associated diseases (PCVAD), before and after 1 y of PCV2 gilt and sow vaccination. Fresh feces from the floor (5 pens/age/farm) and 5 blood samples (1/pen) were collected at 3, 9, 15, 21 wk. Individual feces and blood samples were collected from 5 gilts and 15 sows. Sampling was repeated 1 y after vaccination. Quantitative PCR on feces, PCV2 antibodies in blood serum and cell-mediated immunity were investigated. Before vaccination, pigs of PCVAD-AH had higher viral load in feces (9 and 15 wk), lower IgG and higher IgM (3 wk) and lower lymphocyte counts (9 and 15 wk) suggesting immunosuppression. Vaccination reduced viral load in growers, increased IgG (3 wk) suggesting improved maternal immunity, reduced IgM (3 wk), increased total antibody titers in sows and increased CD79a cells in the pigs.
MeSH term(s)	Animals ; CD79 Antigens/blood ; Circoviridae Infections/prevention & control ; Circoviridae Infections/veterinary ; Circoviridae Infections/virology ; Circovirus ; Feces/virology ; Female ; Immunity, Cellular ; Real-Time Polymerase Chain Reaction ; Swine ; Swine Diseases/immunology ; Swine Diseases/prevention & control ; Swine Diseases/virology ; Viral Vaccines/administration & dosage
Chemical Substances	CD79 Antigens ; Viral Vaccines
Language	English
Publishing date	2016-06
Publishing country	Canada
Document type	Clinical Trial ; Journal Article
ZDB-ID	41603-4
ISSN	0008-5286
ISSN	0008-5286
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 572: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.

Van Damme, Pierre / Bouillette-Marussig, Myriam / Hens, Annick / De Coster, Ilse / Depuydt, Christophe / Goubier, Anne / Van Tendeloo, Viggo / Cools, Nathalie / Goossens, Herman / Hercend, Thierry / Timmerman, Benedikt / Bissery, Marie-Christine

Clinical cancer research : an official journal of the American Association for Cancer Research

2016 Volume 22, Issue 13, Page(s) 3238–3248

Abstract: Purpose: Women infected with human papillomavirus (HPV) with normal cytology to mild abnormalities currently have no treatment options other than watchful waiting or surgery if high-grade cervical lesions or cancer develop. A therapeutic vaccine would ... ...

Abstract	Purpose: Women infected with human papillomavirus (HPV) with normal cytology to mild abnormalities currently have no treatment options other than watchful waiting or surgery if high-grade cervical lesions or cancer develop. A therapeutic vaccine would offer the possibility of preventing high-grade lesions in HPV-infected women. GTL001 is a therapeutic vaccine composed of recombinant HPV16 and HPV18 E7 proteins fused to catalytically inactive Bordetella pertussis CyaA. This study examined the tolerability and immunogenicity of GTL001 in women infected with HPV16 or HPV18 with normal cytology. Experimental design: This was a phase I trial (EudraCT No. 2010-018629-21). In an open-label part, subjects received two intradermal vaccinations 6 weeks apart of 100 or 600 μg GTL001 + topical 5% imiquimod cream at the injection site. In a double-blind part, subjects were randomized 2:1:1 to two vaccinations 6 weeks apart of 600 μg GTL001 + imiquimod, 600 μg GTL001 + placebo cream, or placebo + imiquimod. Results: Forty-seven women were included. No dropouts, treatment-related serious adverse events, or dose-limiting toxicities occurred. Local reactions were transient and mostly mild or moderate. HPV16/18 viral load decreased the most in the 600 μg GTL001 + imiquimod group. In post hoc analyses, the 600 μg GTL001 + imiquimod group had the highest rates of initial and sustained HPV16/18 clearance. Imiquimod increased antigen-specific T-cell response rates but not rates of solicited reactions. All subjects seroconverted to CyaA. Conclusions: For women infected with HPV16 or HPV18 with normal cervical cytology, GTL001 was immunogenic and had acceptable safety profile. Clin Cancer Res; 22(13); 3238-48. ©2016 AACR.
MeSH term(s)	Adjuvants, Immunologic/therapeutic use ; Adolescent ; Adult ; Aminoquinolines/therapeutic use ; Cervix Uteri/cytology ; DNA-Binding Proteins/immunology ; Double-Blind Method ; Female ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Middle Aged ; Oncogene Proteins, Viral/immunology ; Papillomavirus E7 Proteins/immunology ; Papillomavirus Infections/virology ; Papillomavirus Vaccines/immunology ; T-Lymphocytes/immunology ; Uterine Cervical Neoplasms/prevention & control ; Uterine Cervical Neoplasms/virology ; Vaccination ; Viral Load/drug effects ; Young Adult
Chemical Substances	Adjuvants, Immunologic ; Aminoquinolines ; DNA-Binding Proteins ; E7 protein, Human papillomavirus type 18 ; Oncogene Proteins, Viral ; Papillomavirus E7 Proteins ; Papillomavirus Vaccines ; oncogene protein E7, Human papillomavirus type 16 ; imiquimod (P1QW714R7M)
Language	English
Publishing date	2016-06-01
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-16-0085
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito